Buy Gsk Shares -

: 2025 revenue hit £32.7bn (up 7%), driven by high-margin specialty medicines like HIV and Respiratory treatments.

As of late April 2026, (LSE: GSK / NYSE: GSK) has shifted from being a "disappointing" pharmaceutical giant to a momentum-driven stock. After years of underperformance, shares have surged over 16% in 2026 alone and roughly 59% over the past 12 months , significantly outperforming the FTSE 100.

Are you considering GSK primarily for its or for long-term growth in its oncology pipeline? buy gsk shares

: Global drug-pricing reforms and regulatory uncertainty in major markets like the US and China continue to pose valuation risks.

: The payout ratio sits at a healthy 38%–51% of earnings, suggesting the dividend is well-covered by cash flow. ⚠️ The Bear Case: Risks to Watch : 2025 revenue hit £32

: While long-term momentum is high, short-term technical indicators show a recent consolidation phase , with some analysts suggesting the stock is a "hold" or "reduce" candidate at current levels after hitting recent peaks.

: Major product approvals are expected in 2026 for Bepirovirsen (Chronic Hepatitis B) and Tebipenem (UTIs). Are you considering GSK primarily for its or

: The total 2025 dividend was 66p (up 8.2% from 2024). Management has signaled an expected increase to 70p for 2026.